Your session is about to expire
← Back to Search
Sotorasib for Advanced Non-Small Cell Lung Cancer (CodeBreaK201 Trial)
CodeBreaK201 Trial Summary
This trial is testing a new cancer drug to see if it is effective at treating tumors that have a specific genetic mutation.
CodeBreaK201 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCodeBreaK201 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CodeBreaK201 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had radiation therapy in the last 2 weeks.I am not taking strong medications that affect liver enzymes or certain stomach acid drugs.I have not had a heart attack in the last 6 months.I am fully active or restricted in physically strenuous activity but can do light work.My cancer is at stage IV and I haven't received treatment for this stage yet.My cancer has a PD-L1 score under 1% or an STK11 mutation.My lung cancer is a mix of small-cell and non-small cell types.I cannot take medicine by mouth.I am 18 or older with non-small cell lung cancer.I cannot have CT or MRI scans with contrast.My lung cancer has a specific KRAS G12C mutation.I do not have any active cancer spread to my brain.My cancer can be measured by standard criteria.
- Group 1: Sotorasib: 960 mg Daily
- Group 2: Sotorasib: 240 mg Daily
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you provide a summary of the experiments that have utilized Sotorasib?
"The initial trial of Sotorasib was conducted at Centre Hospitalier Intercommunal de Créteil in 2018. Subsequently, 5 studies have been completed and 11 currently active trials are being held in McKinney, New york and other locations."
Are there any still opportunities to join this trial?
"According to clinicaltrials.gov, this research study is currently not enrolling new patients since its last update on November 29th 2022. While the trial has concluded recruitment for now, there are still 1426 other trials actively seeking participants."
How many individuals are being accepted into this medical trial?
"This research trial is no longer seeking enrolment. It was first posted on January 28th 2022, and the latest update came out November 29th 2022. If you are in search of other studies, there are currently 1415 clinical trials for non-small cell lung cancer that have open admission as well 11 Sotorasib related projects admitting new participants."
What potentially harmful effects can Sotorasib have on individuals?
"Sotorasib's safety is rated a 2 as there are only some reports of its efficacy, but the data on its security has been established."
What indications is Sotorasib commonly prescribed to treat?
"Sotorasib is mostly used to treat conditions that were unresponsive to prior platinum therapy and can be applied in the form of a therapeutic procedure, one systemic treatment regimen, or malignant neoplasms."
Are there numerous locations in the city that are conducting this experiment?
"This clinical trial is being conducted at 35 different medical centres and hospitals, including Texas Oncology- Mckinney in McKinney, Texas Oncology-Dallas Presbyterian Hospital in New york, and Laura and Isaac Perlmutter Cancer Center at New York University Langone in Syracuse."
Is this research innovative and cutting-edge?
"Research into Sotorasib began in 2018, and after a successful initial trial sponsored by Amgen involving 713 participants, the drug was approved for Phases 1 & 2. Currently 11 clinical trials are taking place worldwide across 28 countries in 632 cities."
Share this study with friends
Copy Link
Messenger